TTVR STRONG Study for Tricuspid Regurgitation with EVOQUE
This study is looking at the long-term health of people with severe Tricuspid Regurgitation (a heart valve problem) who have received a Transcatheter Tricuspid Valve Replacement (TTVR) using the EVOQUE device. It aims to understand how well the EVOQUE device works in real-world settings. To join, you must be eligible for Medicare, have severe Tricuspid Regurgitation, and either have already received an EVOQUE device or be eligible for one. The study will measure success by looking at a combination of all-cause death or hospital stays for heart failure over two years. The current status of this study is unclear.
- Study design
- This is an observational study that will look back at information from 2044 participants. It is not randomized, meaning participants are not randomly assigned to different treatment groups.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants' health outcomes will be measured for two years after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
TTVR STRONG Under Coverage With Evidence Development (CED) Study
At a glance
Conditions
NCT06833476
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Edwards Lifesciences
Irvine, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Composite (All-Cause Death or Heart Failure Hospitalization)2 years
Time to death or heart failure hospitalization after time zero